Compare Natera Inc. Common Stock (NTRA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Tenet Healthcare Corporation — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Tenet Healthcare Corporation trades at $271.76 (market cap $21.49B). The key difference: Natera Inc. Common Stock is far larger — about 2.7× Tenet Healthcare Corporation's market cap, and Tenet Healthcare Corporation is more actively traded (599,998 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Tenet Healthcare Corporation for 16 Days on average.
| NTRA | THC | |
|---|---|---|
Market Cap | $57.03B | $21.49B |
Volume | 1,131,157 | 599,998 |
Sector | Health | Health |
52-Week High | $425.64 | $280.77 |
52-Week Low | $179.42 | $161.37 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $56.18B | $32.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Tenet Healthcare (THC) trades at $266.91, down 0.69% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats and impressive profitability metrics including 82.83% gross margins and 53.31% ROE. Recent news highlights continued investor interest and upcoming Q3 2026 earnings release on October 29.
THC presents a compelling investment case with attractive valuation (P/E 10.32), strong analyst support (81% buy rating), and 6.2% upside to consensus target of $283.36. Key risks include cash flow sustainability for capital return strategy and potential surgical volume pressures. The stock's combination of value pricing and growth execution supports continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
